AARTIDRUGS / Q4-FY26 / risks

Keep the risk register visible.

Aarti Drugs · Material risks, their source context, and severity in the latest available quarter.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

WatchQ4-FY26 · 2026-04-30Back to quarter ↗

Risk intelligence

Material risks this quarter

Sustained high crude prices hurting antibiotic demand

If crude remains above $110-120, domestic antibiotic demand may decline due to price sensitivity, impacting volumes.

high

Salicylic acid plant turnaround delayed

Salicylic acid production remains shut due to equipment delays and variable losses; restart depends on successful installation and testing.

medium

Methylamine ramp-up dependent on metformin expansion

Higher utilization of the methylamine plant requires commensurate metformin production expansion, which is still underway.

medium

Geopolitical disruptions impacting raw material supply

West Asia war caused ammonia shortages in March; further escalation could disrupt key raw material availability.

high